HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

Abstract
This Phase I study of MMI270, an p.o. administered matrix metalloproteinase inhibitor, assessed toxicity, pharmacokinetics, and tumor response data and investigated markers of biological activity to recommend a dose for Phase II studies. MMI270 was administered continuously at seven dose levels (50 mg once daily to 600 mg three times/day). Patients were evaluated for toxicity and tumor response, and blood and urine samples were taken for pharmacokinetics, bone resorption markers, direct targets of the inhibitor [matrix metalloproteinase-2 (MMP-2), MMP-8, and MMP-9], indirect targets [tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, basic fibroblast growth factor, vascular endothelial growth factor, vascular cell adhesion molecule-1, soluble urokinase plasminogen activator receptor, and cathepsins B and H] and for a tumor necrosis factor-alpha cytokine release assay. Ninety-two patients were entered. There was no myelotoxicity. Eighteen patients developed a widespread maculopapular rash, which increased in frequency and severity at doses > or = 300 mg bid. Thirty nine patients developed musculoskeletal side effects, which were related to duration of treatment, not to dose level. Pharmacokinetics were linear, and MMI270 was rapidly absorbed and eliminated with minimal accumulation on chronic dosing. Sustained plasma concentrations in excess of 4 x mean IC(50) for the target enzymes were observed at dose levels > or = 150 mg bid. There were no tumor regressions; however, 19 patients had stable disease for > or = 90 days. There was a dose-response increase of MMP-2 and TIMP-1 with MMI270. Transient effects on the bone resorption markers were detected. MMI270 was generally well tolerated, with adequate plasma levels for target enzyme inhibition. The two main toxicities were rash, resulting in a maximum tolerated dose of 300 mg bid and musculoskeletal side effects. Biological marker data indicate drug effects. The rise in TIMP-1 suggests that a reflex rise in inhibitors could modify the effects of MMI270. The recommended Phase II dose is 300 mg bid.
AuthorsN C Levitt, F A Eskens, K J O'Byrne, D J Propper, L J Denis, S J Owen, L Choi, J A Foekens, S Wilner, J M Wood, M Nakajima, D C Talbot, W P Steward, A L Harris, J Verweij
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 7 Issue 7 Pg. 1912-22 (Jul 2001) ISSN: 1078-0432 [Print] United States
PMID11448904 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)
Chemical References
  • CGS 27023A
  • Hydroxamic Acids
  • Protease Inhibitors
  • Pyrazines
  • Sulfonamides
  • Metalloendopeptidases
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Area Under Curve
  • Dose-Response Relationship, Drug
  • Exanthema (chemically induced)
  • Female
  • Humans
  • Hydroxamic Acids
  • Male
  • Metabolic Clearance Rate
  • Metalloendopeptidases (antagonists & inhibitors)
  • Middle Aged
  • Musculoskeletal Diseases (chemically induced)
  • Nausea (chemically induced)
  • Neoplasms (drug therapy, metabolism)
  • Protease Inhibitors (adverse effects, pharmacokinetics, therapeutic use)
  • Pyrazines
  • Sulfonamides
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: